Shire

Shire SHP

This security is delisted

Dividend Summary


The previous Shire dividend was 41.6c and it went ex over 3 years ago and it was paid 3 years ago.
There are typically 2 dividends per year (excluding specials), and the dividend cover is approximately 13.8.

Latest Dividends
Summary Previous dividend Next dividend
Status Forecast
Type Final
Per share 29.873p (41.6c)
Declaration date
Ex-div date 04 Mar 2021 (Thu)
Pay date 21 Apr 2021 (Wed)

Enter the number of Shire shares you hold and we'll calculate your dividend payments:

Previous Payment
Next Payment
Forecast Accuracy
68%
Our premium tools have predicted Shire with 68% accuracy.
Dividend Yield Today
0.0%
The dividend yield is calculated by dividing the annual dividend payment by the prevailing share price
The table below shows the full dividend history for Shire
Status Type Decl. date Ex-div date Pay date Decl. Currency Forecast amount Decl. amount Accuracy
Forecast Final 04 Mar 2021 21 Apr 2021 USD Sign up
Forecast Interim 03 Sep 2020 16 Oct 2020 USD Sign up
Forecast Final 05 Mar 2020 22 Apr 2020 USD Sign up
Forecast Interim 05 Sep 2019 18 Oct 2019 USD Sign up
Forecast Final 07 Mar 2019 23 Apr 2019 USD Sign up
Paid Interim 06 Sep 2018 19 Oct 2018 USD 4.1p 5.6c 😞
Paid Final 08 Mar 2018 24 Apr 2018 USD 23p 29.79c 😒
Paid Interim 03 Aug 2017 07 Sep 2017 20 Oct 2017 USD 3.8p 5.09c 😒
Paid Final 16 Feb 2017 09 Mar 2017 25 Apr 2017 USD 25.7c
Paid Interim 02 Aug 2016 08 Sep 2016 07 Oct 2016 USD 3.1p 4.63c 😞
Paid Final 10 Mar 2016 12 Apr 2016 USD 22.16c
Paid Interim 23 Jul 2015 03 Sep 2015 02 Oct 2015 USD 4.21c
Paid Final 12 Feb 2015 12 Mar 2015 14 Apr 2015 USD 19.09c
Paid Interim 01 May 2014 03 Sep 2014 03 Oct 2014 USD 3.83c
Paid Final 24 Oct 2013 05 Mar 2014 08 Apr 2014 USD 16.93c
Paid Interim 25 Jul 2013 04 Sep 2013 03 Oct 2013 USD 3c
Paid Final 14 Feb 2013 06 Mar 2013 09 Apr 2013 USD 14.6c
Paid Interim 05 Sep 2012 04 Oct 2012 USD 2.73c
Paid Final 07 Mar 2012 12 Apr 2012 GBP 7.96p
Paid Interim 07 Sep 2011 06 Oct 2011 GBP 1.52p
Paid Final 09 Mar 2011 07 Apr 2011 GBP 6.73p
Paid Interim 08 Sep 2010 07 Oct 2010 GBP 1.41p
Paid Final 31 Dec 2009 31 Dec 2009 GBP 7.21p
Paid Final 31 Dec 2008 31 Dec 2008 GBP 6.55p
Paid Final 31 Dec 2007 31 Dec 2007 GBP 4.36p
Paid Final 31 Dec 2006 31 Dec 2006 GBP 3.74p
Year Amount Change
2006 3.74p
2007 4.36p
16.6%
2008 6.55p
50.2%
2009 7.21p
10.1%
2010 8.14p
12.9%
2011 9.48p
16.5%
2012 11.13p
17.4%
2013 12.12p
8.9%
2014 14.65p
20.9%
2015 18.01p
22.9%
2016 24.16p
34.1%
2017 25.196513p
4.3%
2018 30.382494p
20.6%
2019 35.529893p
16.9%
2020 35.109019p
-1.2%

Shire Optimized Dividend Chart

The chart below shows the optimized dividends for this security over a rolling 12-month period.
Dividend Yield Today
0.0%
Optimized Yield
Sign Up Required
52 Week High
0.0% on  
52 Week Low
0.0% on  
Next Ex-Div-Date Countdown
Sign Up Required

About Shire

Shire is a leading UK pharmaceutical company. It's products include products include include Vyvanse, Adderall, XR, Intuniv, Lialda, Pentasa, Fosrenol, Replagal, Elaprase, Vpriv, Firazyr and Dermagraft.

Sector
Pharmaceuticals & Biotechnology
Country
United Kingdom
Share Price
£45.06 (closing price on 04 Nov 2020)
Shares in Issue
562 million
Market Cap
£25.3bn
Dividend Cover
How many times is the dividend covered by company income. A cover of 1 means all income is paid out in dividends
13.8
CADI
The Consecutive Annual Dividend Increases - the number of years this company has been increasing its dividends
10+
Market Indices
FTSE 350, FTSE 100, CBOE 350, CBOE 100
Investor Relations URL
Sign Up Required
Financial Calendar URL
Sign Up Required
Dividend History URL
Sign Up Required
Home Page URL
https://www.shire.com
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
Financial Highlights Full Year 2012Product sales $4,407 million +12%Product sales excluding ADDERALL XR $3,978 million +16%Total revenues $4,681 million +10%Non GAAP operating income $1,474 million +9%US GAAP operating income $949 million -14%Non GAAP diluted earnings per ADS $6.10 +14%US GAAP diluted earnings per ADS $3.93 -13%Non GAAP cash generation $1,637 million +18%Non GAAP free cash flow $1,256 million +43%US GAAP net cash provided by operating activities $1,383 million +29%DIVIDENDIn respect of the six months ended December 31, 2012 the Board has resolved topay an interim dividend of 14.60 US cents per ordinary share (2011: 12.59 UScents per ordinary share).Dividend payments will be made in Pounds Sterling to ordinary shareholders andin US Dollars to holders of ADSs. A dividend of 9.39 pence per ordinary share(2011: 7.96 pence) and 43.80 US cents per ADS (2011: 37.77 US cents) will bepaid on April 9, 2013 to shareholders on the register as at the close ofbusiness on March 8, 2013.Together with the first interim payment of 2.73 US cents per ordinary share(2011: 2.48 US cents per ordinary share), this represents total dividends for2012 of 17.33 US cents per ordinary share (2011: 15.07 US cents per ordinaryshare), an increase of 15% in US Dollar terms.Angus Russell, Chief Executive Officer, commented:"It's been another strong year for Shire with 12% growth in product sales and14% growth in Non GAAP earnings which have driven particularly strong cashgeneration. While delivering strong financial results, we continue to invest inour emerging late stage R&D pipeline.Our ADHD portfolio is performing very well in a growing global market and wesee further growth going forward. The positive opinion received from theEuropean regulators for ELVANSE is a significant milestone and we're nowpreparing for country launches in some of the largest markets in Europe. Allour rare disease treatments continue to grow and we saw particularly strongperformance from FIRAZYR in its first full year in the US market. We advancedour plans for developing our Regenerative Medicine business with theacquisition of VASCUGEL and the approval of DERMAGRAFT in Canada.Our late stage R&D pipeline now holds the prospect of future growth from LDX(the active ingredient in VYVANSE) in major depressive disorder, binge eatingdisorder and negative symptoms of schizophrenia. Our intrathecal programs arealso progressing well as we plan the next clinical trials for Hunter CNS andSanfilippo A and continue to enrol MLD patients into the ongoing Phase 1/2trial. A phase 2b study of SPD602, our iron chelating product, is underway andheadline results are expected later this year.We've completed a number of in-licensing deals and acquisitions in 2012,bringing us new technology platforms in rare diseases, hematology and a rangeof early stage and exciting differentiated treatments.We've put in place our leadership succession plan. Dr. Flemming Ørnskov joinedus at the beginning of January and is familiarising himself with the businessbefore he assumes the role of CEO at the end of April. His considerablepharmaceutical and international experience will benefit Shire going forward.Today we announce that Sylvie Gregoire, President of our HGT business, hasdecided to leave Shire at the end of March, after five years. We're gratefulfor her significant contributions to the growth of Shire through establishingHGT as a leader in rare diseases.Shire is in great shape, with the current business performing well, a promisingpipeline of new growth opportunities, and the strategy in place to deliver anexciting future. As we look forward to the year ahead, we expect our financialresults to show further growth in line with current consensus earningsexpectations for 2013(1)."
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited
DividendMax Limited